Compare SSM & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSM | SNGX |
|---|---|---|
| Founded | N/A | 1987 |
| Country | Germany | United States |
| Employees | 43 | 16 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.3M |
| IPO Year | N/A | 2006 |
| Metric | SSM | SNGX |
|---|---|---|
| Price | $6.90 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 1.6K | ★ 110.0K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.34 | $1.02 |
| 52 Week High | $10.47 | $6.23 |
| Indicator | SSM | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 48.60 |
| Support Level | $6.70 | $1.19 |
| Resistance Level | $7.00 | $1.22 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 9.09 | 44.35 |
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).